新辅助治疗
肺癌
医学
肿瘤科
癌症研究
内科学
癌症
乳腺癌
作者
Marco Sposito,Serena Eccher,Ilaria Mariangela Scaglione,Alice Avancini,Antônio Rossi,Sara Pilotto,Lorenzo Belluomini
标识
DOI:10.1080/14712598.2024.2408292
摘要
While surgical resection is the cornerstone of treatment for resectable lung cancer, neoadjuvant/adjuvant chemotherapy has shown limited improvement in survival rates over the past decades. With the success of immune checkpoint inhibitors (ICIs) in advanced NSCLC, there is growing interest in their application in earlier stages of the disease. Recent approvals for neoadjuvant/adjuvant ICIs in stage II-IIIA NSCLC highlight this shift in treatment paradigms.
科研通智能强力驱动
Strongly Powered by AbleSci AI